Dr. Gwynn D. Long

I study disorders of the bone marrow and bone marrow failure syndromes. I also see some leukemias and lymphomas and other blood malignancies. Duke offers a very personalized, individualized level of care to each patient. Nobody is the same, so we take the whole patient, we listen to them, and we offer our best recommendations for treatment options. We offer some of the latest treatment options that are available, usually in the setting of a clinical trial. If not, we offer the latest advancement in the field. When I was going through medical school, molecular biology was the new field. Everything was being described as a new cancer-causing gene. And to me that was so appealing – we’re going to figure out what causes cancer and new ways to treat it. That’s what really brought me into the hematology oncology world – things were being discovered that were new and exciting and hopefully would lead to new treatment options. Duke offers an extremely high standard of care. Though we’re not always successful and the disease sometimes wins, our goal is to give the patients the best possible care. Dr. De Castro Iii is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Joshua Zeidner is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Zeidner is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Zeidner is currently accepting new patients.

I focus on treating patients with blood cancers who are considering stem cell or bone marrow transplantation. There have been significant improvements in transplantation over the last 20 years, which has improved outcomes. These improvements include the ability to use lower doses of chemotherapy to reduce toxicity for patients, as well as strategies to reduce the risk of relapse. I am interested in using new therapies and approaches to improve outcomes after stem cell transplantation for blood cancers. It is important to work together with patients to determine their goals for treatment and select the best path forward. I have enjoyed working with patients and their families for many years after their transplant. Dr. Alyea-Iii is rated as an Advanced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, and Bone Marrow Transplant.